ECE2014 Poster Presentations Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (108 abstracts)
Belorussian State Medical Institution, Minsk, Belarus.
Objective: The aim was to compare the effectiveness of the bromocriptine and cabergoline treatment of the women with microprolactinomas.
Materials and methods: 82 women with microprolactinomas were included in this study (51 patients received bromocriptine (Group 1) and 31 cabergoline (Group 2)) with MRI-control after the first year of treatment (11 women from Group 1; 7 from Group 2), the second (27 women from Group 1; 15 from Group 2) and third year of treatment (13 women from Group 1; 9 from Group 2). The drug dosage was titrated until the normalization of the serum prolactin level. The selective method of the statistical analysis was used. The changes were considered as positive if the size reduction of microprolactinomas was not <15%, negative the enlargement was not <15%. Insignificant or absent changes were considered as no dynamics.
Results:
MRI-dynamics | Group 1 1 year (n=11) | Group 2 1 year (n=7) | Group 1 2 year (n=27) | Group 2 2 year (n=15) | Group 1 3 year (n=13) | Group 2 3 year (n=9) | Group 1 (n=51) (%) | Group 2 (n=31) (%) |
Positive | 2 | 4 | 9 | 8 | 1 | 4 | 12 (24%)* | 16 (52%)* |
Negative | 2 | 0 | 1 | 0 | 3 | 1 | 6 (11%) | 1 (3%) |
Without dynamics | 7 | 3 | 17 | 7 | 9 | 4 | 33 (65%) | 14 (45%) |
MRI-dynamics | Group 1 1 year (n=11) | Group 2 1 year (n=7) | Group 1 2 year (n=27) | Group 2 2 year (n=15) | Group 1 3 year (n=13) | Group 2 3 year (n=9) | Group 1 (n=51) (%) | Group 2 (n=31) (%) |
Positive | 2 | 4 | 9 | 8 | 1 | 4 | 12 (24%)* | 16 (52%)* |
Negative | 2 | 0 | 1 | 0 | 3 | 1 | 6 (11%) | 1 (3%) |
Without dynamics | 7 | 3 | 17 | 7 | 9 | 4 | 33 (65%) | 14 (45%) |
Conclusions: It was pointed out that the achievement of positive dynamics in women with microprolactinomas receiving treatment with dopamine agonists for 13 years was more than two times more frequently with cabergoline than bromocriptine. The findings suggest that cabergoline is preferable to bromocriptine in the treatment of the women with microprolactinomas.